TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 2070704

Group type: EXPERIMENTAL
Intervention: Maalox TC (three tablets four times daily)
Number of subjects: 79

Group type: COMPARATOR
Intervention: Ranitidine (150 mg twice daily)
Number of subjects: 79

Group type: EXPERIMENTAL
Intervention: Both treatments
Number of subjects: 79

Group type: EXPERIMENTAL
Intervention: Maalox TC
Number of subjects: 79
Study: 6841505

Group type: EXPERIMENTAL
Intervention: Reading remediation emphasizing phonetic decoding
Number of subjects: 61

Group type: COMPARATOR
Intervention: Control group (instruction in other subjects)
Number of subjects: 61
Study: 31393353

Group type: EXPERIMENTAL
Intervention: Music therapy with cognitive-behavioral therapy (MTCBP) for 12 weeks
Number of subjects: 155

Group type: COMPARATOR
Intervention: Waiting-list control group
Number of subjects: 155

Group type: EXPERIMENTAL
Intervention: Music therapy with cognitive-behavioral therapy (MTCBP)
Number of subjects: 155
Study: 30334434

Group type: EXPERIMENTAL
Intervention: Administration of oral probiotics, dosage and duration not specified
Number of subjects: 0
Study: 27736051

Group type: EXPERIMENTAL
Intervention: N-Acetylcysteine (2,400 mg/d)
Number of subjects: 35

Group type: COMPARATOR
Intervention: Placebo plus cognitive-behavioral therapy for SUD
Number of subjects: 35
Study: 24420987

Group type: EXPERIMENTAL
Intervention: Oral sildenafil
Number of subjects: 47

Group type: COMPARATOR
Intervention: Inhaled iloprost
Number of subjects: 47
Study: 22404182

Group type: EXPERIMENTAL
Intervention: Thalidomide + dexamethasone (Thal-Dex)
Number of subjects: 131

Group type: COMPARATOR
Intervention: Bortezomib + dexamethasone (Bort-Dex)
Number of subjects: 131
Study: 20642198

Group type: EXPERIMENTAL
Intervention: Self-management education (contract to adopt behavior, workbook, weekly reinforcements for 12 weeks, frequent follow-up visits)
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Self-management education
Number of subjects: 90

Group type: COMPARATOR
Intervention: Asthma brochures and social support (control group)
Number of subjects: 90
Study: 17661935

Group type: EXPERIMENTAL
Intervention: HA gel
Number of subjects: 15

Group type: COMPARATOR
Intervention: hylan B plus gel
Number of subjects: 15
Study: 17823136

Group type: EXPERIMENTAL
Intervention: Permanent pacemaker (P group, n = 30)
Number of subjects: 60

Group type: COMPARATOR
Intervention: No pacing (NP group, n = 30)
Number of subjects: 60
Study: 14738022

Group type: EXPERIMENTAL
Intervention: Bilateral ascending uterine artery ligation
Number of subjects: 70

Group type: COMPARATOR
Intervention: Tourniquet use (Control)
Number of subjects: 70
Study: 10718074

Group type: COMPARATOR
Intervention: Control + caffeine (Cc)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Control + placebo (Cp)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Sleep deprived + caffeine (SDc)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Sleep deprived + placebo (SDp)
Number of subjects: 40
Study: 9196163

Group type: EXPERIMENTAL
Intervention: ACTH 2 mg plus 1 mg on day 4
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: ACTH 1 mg
Number of subjects: 150

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 150
Study: 1546123

Group type: EXPERIMENTAL
Intervention: Moclobemide (450 mg/day, reduced to 300 mg/day after 4 weeks if required)
Number of subjects: 184

Group type: COMPARATOR
Intervention: Amineptine (200 mg/day, reduced to 100 mg/day after 4 weeks if required)
Number of subjects: 184

Group type: EXPERIMENTAL
Intervention: Moclobemide
Number of subjects: 184

Group type: COMPARATOR
Intervention: Amineptine
Number of subjects: 184
Study: 2864663

Group type: EXPERIMENTAL
Intervention: Somatostatin
Number of subjects: 15

Group type: COMPARATOR
Intervention: Intensive antacid and thrombin
Number of subjects: 15
Study: 31072304

Group type: EXPERIMENTAL
Intervention: Participants in the RCT
Number of subjects: 0

Group type: COMPARATOR
Intervention: Non-participants
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Participants (BMQ)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Non-participants (BMQ)
Number of subjects: 0
Study: 29210902

Group type: EXPERIMENTAL
Intervention: CO2 insufflation
Number of subjects: 40

Group type: COMPARATOR
Intervention: Air insufflation
Number of subjects: 40
Study: 26289613

Group type: EXPERIMENTAL
Intervention: eHealth intervention (monthly teleassistance)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Traditional care
Number of subjects: 0
Study: 24767806

Group type: EXPERIMENTAL
Intervention: Jaw relaxation for 20 minutes before dressing changes
Number of subjects: 100

Group type: COMPARATOR
Intervention: Usual care (control group)
Number of subjects: 100
Study: 22336748

Group type: COMPARATOR
Intervention: Group CBT
Number of subjects: 140

Group type: COMPARATOR
Intervention: Self-help CBT
Number of subjects: 140

Group type: EXPERIMENTAL
Intervention: No Treatment Control (NTC)
Number of subjects: 140
Study: 20578091

Group type: EXPERIMENTAL
Intervention: Transradial radiation protection board (TRPB)
Number of subjects: 106

Group type: COMPARATOR
Intervention: Standard lead apron and shielding without TRPB
Number of subjects: 106
Study: 19186349

Group type: EXPERIMENTAL
Intervention: Ritonavir (R)
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: Ritonavir with CVH (R+, CVH+)
Number of subjects: 26

Group type: COMPARATOR
Intervention: No Ritonavir (no R)
Number of subjects: 26
Study: 15927063

Group type: EXPERIMENTAL
Intervention: Single inhalation of hyaluronic acid
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Baseline desmosines in plasma and urine
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Urinary desmosine levels
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Fibrinogen fragments in plasma
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: JM403 in urine
Number of subjects: 12
Study: 12446160

Group type: EXPERIMENTAL
Intervention: Assistive loading
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Resistive loading
Number of subjects: 11

Group type: COMPARATOR
Intervention: Free loading
Number of subjects: 11

Group type: COMPARATOR
Intervention: No loading
Number of subjects: 11
Study: 10340882

Group type: EXPERIMENTAL
Intervention: Breast-Conservation Therapy (BCT)
Number of subjects: 363

Group type: COMPARATOR
Intervention: Mastectomy
Number of subjects: 363
Study: 7488812

Group type: EXPERIMENTAL
Intervention: Treatment for 6 months (protocol C)
Number of subjects: 184

Group type: EXPERIMENTAL
Intervention: Treatment for 2 months (protocol B)
Number of subjects: 184

Group type: EXPERIMENTAL
Intervention: Treatment for 3 months (protocol A)
Number of subjects: 184
Study: 1928875

Group type: EXPERIMENTAL
Intervention: Activated charcoal (AC) administered 15 minutes after acetaminophen
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Activated charcoal (AC) administered 30 minutes after acetaminophen
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Activated charcoal (AC) administered 120 minutes after acetaminophen
Number of subjects: 10

Group type: COMPARATOR
Intervention: Control phase (no AC)
Number of subjects: 10
Study: 6869761

Group type: EXPERIMENTAL
Intervention: Etomidate infusion
Number of subjects: 3

Group type: EXPERIMENTAL
Intervention: Fentanyl infusion
Number of subjects: 3

Group type: EXPERIMENTAL
Intervention: Rapid infusion of etomidate
Number of subjects: 3

Group type: COMPARATOR
Intervention: Thiopentone bolus injection
Number of subjects: 3

Group type: EXPERIMENTAL
Intervention: All techniques (etomidate, fentanyl, thiopentone)
Number of subjects: 3
Study: 31623894

Group type: EXPERIMENTAL
Intervention: Tranexamic acid (loading dose 1 g over 10 min then infusion of 1 g over 8 h)
Number of subjects: 12737

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12737
Study: 30028656

Group type: EXPERIMENTAL
Intervention: Cisplatin
Number of subjects: 531

Group type: COMPARATOR
Intervention: Gemcitabine or pemetrexed without cisplatin
Number of subjects: 531
Study: 27183545

Group type: EXPERIMENTAL
Intervention: Fluocinolone acetonide (FAc) 0.5 µg/day
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Fluocinolone acetonide (FAc) 0.2 µg/day
Number of subjects: 0

Group type: COMPARATOR
Intervention: Sham control
Number of subjects: 0
Study: 24346280

Group type: EXPERIMENTAL
Intervention: Lapatinib administered 1 h after a low-fat meal
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Lapatinib administered 1 h after a high-fat meal
Number of subjects: 25

Group type: COMPARATOR
Intervention: Lapatinib administered 1 h before a low-fat meal
Number of subjects: 25
Study: 22041970

Group type: EXPERIMENTAL
Intervention: Oral rehydration solution (ORS) group
Number of subjects: 300

Group type: COMPARATOR
Intervention: Fasting group
Number of subjects: 300
Study: 19474284

Group type: EXPERIMENTAL
Intervention: Random PTF (n = 620)
Number of subjects: 806

Group type: EXPERIMENTAL
Intervention: Matched PTF (n = 86)
Number of subjects: 806

Group type: EXPERIMENTAL
Intervention: Donor-specific blood transfusion (DST) (n = 100)
Number of subjects: 806

Group type: COMPARATOR
Intervention: Control group (non-immunized female renal transplant recipients who did not receive a PTF)
Number of subjects: 806
Study: 16636870

Group type: EXPERIMENTAL
Intervention: Clazosentan 30 mg/h for 3 h
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Clazosentan 60 mg/h for 6 h
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Clazosentan 30 mg/h for 12 h
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Clazosentan 10 mg/h for 3 h
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Clazosentan infusion
Number of subjects: 8

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study: 16135178

Group type: EXPERIMENTAL
Intervention: Inhaled budesonide (400 microg/puff, twice daily)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study: 14650463

Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study: 9860108

Group type: EXPERIMENTAL
Intervention: Ziprasidone 120 mg/day
Number of subjects: 139

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 139

Group type: EXPERIMENTAL
Intervention: Ziprasidone 40 mg/day
Number of subjects: 139
Study: 8636714

Group type: EXPERIMENTAL
Intervention: Interferon alpha 2a (IFN) treatment
Number of subjects: 18

Group type: COMPARATOR
Intervention: Observation only (Control)
Number of subjects: 18
Study: 2483687

Group type: EXPERIMENTAL
Intervention: Methylprednisolone sodium succinate 125 mg daily infusions
Number of subjects: 173

Group type: EXPERIMENTAL
Intervention: Methylprednisolone sodium succinate
Number of subjects: 173

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 173
Study: 61439

Group type: EXPERIMENTAL
Intervention: Methyldopa ('Aldomet') treatment
Number of subjects: 242

Group type: COMPARATOR
Intervention: Control group (no treatment)
Number of subjects: 242

Group type: EXPERIMENTAL
Intervention: Both groups (treated and control)
Number of subjects: 242

Group type: EXPERIMENTAL
Intervention: Methyldopa treatment
Number of subjects: 242
Study: 30919233

Group type: EXPERIMENTAL
Intervention: Peak-trough-based TDM
Number of subjects: 65

Group type: COMPARATOR
Intervention: Trough-only-based TDM
Number of subjects: 65
Study: 28969327

Group type: EXPERIMENTAL
Intervention: Deep NMB (infusion of rocuronium 2 mg ml -1)
Number of subjects: 128

Group type: COMPARATOR
Intervention: Standard NMB (bolus of rocuronium 10 mg or increased depth of anaesthesia)
Number of subjects: 128

Group type: EXPERIMENTAL
Intervention: Deep NMB
Number of subjects: 128

Group type: COMPARATOR
Intervention: Deep NMB and Standard NMB
Number of subjects: 128
Study: 26255515

Group type: EXPERIMENTAL
Intervention: Auricular point sticking therapy (stimulated on specific points once a week for 4 weeks)
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Combined program of auricular point sticking therapy and TCM psychotherapy (4 weeks treatment)
Number of subjects: 90

Group type: COMPARATOR
Intervention: Western medication group (oral administration of deanxit, one tablet a day for 4 weeks)
Number of subjects: 90
Study: 23153291

Group type: EXPERIMENTAL
Intervention: Low-level laser therapy (LLLT) with wavelength 830 nm, dose of 2 J/cm² and additional spots of 1 J/cm².
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo light treatment (control group).
Number of subjects: 60
Study: 22303699

Group type: EXPERIMENTAL
Intervention: Tramadol hydrochloride sustained release tablets administered at 12h, 24h, 48h postoperation and before cleaning up procession
Number of subjects: 188

Group type: COMPARATOR
Intervention: Control group (no administration of Tramadol)
Number of subjects: 188
Study: 19509011

Group type: EXPERIMENTAL
Intervention: Aerobic exercise (3 months vigorous aerobic exercise, supervised 3 times per week)
Number of subjects: 36

Group type: COMPARATOR
Intervention: Nonaerobic group (no aerobic exercise)
Number of subjects: 36
Study: 16684263

Group type: EXPERIMENTAL
Intervention: Iron plus triple therapy for H. pylori
Number of subjects: 650

Group type: EXPERIMENTAL
Intervention: Iron alone
Number of subjects: 650

Group type: COMPARATOR
Intervention: Continuously infected children (control group)
Number of subjects: 650
Study: 15225901

Group type: EXPERIMENTAL
Intervention: Moderate exercise (ME) intensity (0.55-0.65 x maximal aerobic power)
Number of subjects: 23

Group type: COMPARATOR
Intervention: Low exercise (LE) intensity (0.30-0.40 x maximal aerobic power)
Number of subjects: 23
Study: 16054522

Group type: EXPERIMENTAL
Intervention: Parenteral nutrition supplemented with dipeptide alanyl‐glutamine
Number of subjects: 40

Group type: COMPARATOR
Intervention: Parenteral nutrition (standard)
Number of subjects: 40
Study: 10336000

Group type: EXPERIMENTAL
Intervention: Negatively charged filters applied after 3 days of storage
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Gamma radiation
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Positively charged filters
Number of subjects: 0

Group type: COMPARATOR
Intervention: Untreated apheresis PCs
Number of subjects: 0

Group type: COMPARATOR
Intervention: Buffy coat PCs
Number of subjects: 0
Study: 7554318

Group type: EXPERIMENTAL
Intervention: Oral conjugated equine oestrogen (1.25 mg daily)
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Transdermal 17 beta‐oestradiol (100 micrograms daily)
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Both oestrogen treatments
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Neither oral nor transdermal oestrogen
Number of subjects: 15
Study: 2298404

Group type: EXPERIMENTAL
Intervention: Doxorubicin (DOX) treatment arm (60 mg/m2 starting dose, maximum cumulative dose of 500 mg/m2)
Number of subjects: 181

Group type: COMPARATOR
Intervention: No Doxorubicin (no-DOX arm)
Number of subjects: 181
Study: 7436691

Group type: EXPERIMENTAL
Intervention: Clomipramine hydrochloride
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Doxepin
Number of subjects: 0

Group type: COMPARATOR
Intervention: Tryptophan (L‐tryptophan)
Number of subjects: 0
Study: 31851171

Group type: EXPERIMENTAL
Intervention: Nooclerin (deanol aceglumate)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study: 26811172

Group type: EXPERIMENTAL
Intervention: Participatory supportive return to work program
Number of subjects: 94
Study: 26791477

Group type: EXPERIMENTAL
Intervention: Doxazosin
Number of subjects: 1131

Group type: COMPARATOR
Intervention: Chlorthalidone
Number of subjects: 1131
Study: 24862342

Group type: EXPERIMENTAL
Intervention: Nebulized 3% hypertonic saline (HS)
Number of subjects: 62

Group type: COMPARATOR
Intervention: Normal saline (NS)
Number of subjects: 62
Study: 22072307

Group type: EXPERIMENTAL
Intervention: Combination docetaxel and carboplatin (cDC): weekly docetaxel 30 mg/m² on days 1 and 8 and carboplatin AUC = 6 on day 1, every 3 weeks
Number of subjects: 150

Group type: COMPARATOR
Intervention: Sequential therapy with docetaxel then carboplatin (sDC): docetaxel 30 mg/m² on days 1 and 8 for 6 cycles followed by carboplatin AUC = 6 on day 1 for 6 cycles
Number of subjects: 150
Study: 20541024

Group type: EXPERIMENTAL
Intervention: High-dose steroids plus a second immunosuppressive agent
Number of subjects: 180
Study: 17255748

Group type: EXPERIMENTAL
Intervention: Remune, an inactivated HIV‐1 vaccine
Number of subjects: 0
Study: 15821223

Group type: EXPERIMENTAL
Intervention: N-acetylcysteine (NAC) - continuous infusion starting with 50 mg/kg/4 h followed by 100 mg/kg/24 h for 44 h (n = 18)
Number of subjects: 35

Group type: COMPARATOR
Intervention: Placebo (n = 17)
Number of subjects: 35
Study: 11975151

Group type: EXPERIMENTAL
Intervention: Procedural priming task focusing on similarities
Number of subjects: 0

Group type: COMPARATOR
Intervention: Procedural priming task focusing on differences
Number of subjects: 0
Study: 9813512

Group type: EXPERIMENTAL
Intervention: i.v. clonidine 1 microgram kg‐1
Number of subjects: 100

Group type: COMPARATOR
Intervention: saline bolus
Number of subjects: 100
Study: 8762660

Group type: EXPERIMENTAL
Intervention: Dobesilate of calcium with dexamethasone acetate and lidocaine (Treatment A)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Prednisolone capronate with dibucaine hydrochloride (Treatment B)
Number of subjects: 40
Study: 2496791

Group type: EXPERIMENTAL
Intervention: Omeprazole 30 mg daily for six weeks
Number of subjects: 161

Group type: COMPARATOR
Intervention: Cimetidine 1 g daily for six weeks
Number of subjects: 161
Study: 31285554

Group type: EXPERIMENTAL
Intervention: High P/B ratio (n=63)
Number of subjects: 126

Group type: EXPERIMENTAL
Intervention: High P/B ratio with high HOMA-IR and low fiber intake (n=17)
Number of subjects: 126

Group type: COMPARATOR
Intervention: Low P/B ratio (n=63)
Number of subjects: 126
Study: 31501120

Group type: EXPERIMENTAL
Intervention: Hearing Aids (HAs)
Number of subjects: 4

Group type: EXPERIMENTAL
Intervention: Cochlear Implants (CIs)
Number of subjects: 4

Group type: COMPARATOR
Intervention: Qualitative research (q-COACH)
Number of subjects: 4
Study: 28613971

Group type: EXPERIMENTAL
Intervention: Cognitive Behavior Therapy Self-Help Booklet (CBT-SHB) with usual care
Number of subjects: 332

Group type: COMPARATOR
Intervention: Usual outpatient care alone
Number of subjects: 332
Study: 25727273

Group type: EXPERIMENTAL
Intervention: Manual-turn protocol
Number of subjects: 13

Group type: COMPARATOR
Intervention: Automated-turn protocol
Number of subjects: 13
Study: 24399261

Group type: EXPERIMENTAL
Intervention: Group A (HRA augmented with health promotion and education activities)
Number of subjects: 180

Group type: EXPERIMENTAL
Intervention: Group B (HRA only)
Number of subjects: 180

Group type: COMPARATOR
Intervention: Control Group (no intervention)
Number of subjects: 180
Study: 23034084

Group type: EXPERIMENTAL
Intervention: Diarrhea interventions (DIA)
Number of subjects: 800

Group type: EXPERIMENTAL
Intervention: Dengue interventions (DEN)
Number of subjects: 800

Group type: EXPERIMENTAL
Intervention: Combined diarrhea and dengue interventions (DIADEN)
Number of subjects: 800

Group type: COMPARATOR
Intervention: Control (C)
Number of subjects: 800
Study: 19714630

Group type: EXPERIMENTAL
Intervention: Methotrexate (MTX) alone (> or =10 mg/m(2)/week, maximum dosage 1 mg/kg/week)
Number of subjects: 594

Group type: EXPERIMENTAL
Intervention: Etanercept alone (0.8 mg/kg/week, maximum dose 50 mg)
Number of subjects: 594

Group type: EXPERIMENTAL
Intervention: Etanercept plus Methotrexate (MTX)
Number of subjects: 594

Group type: COMPARATOR
Intervention: All treatment groups (MTX, etanercept, etanercept plus MTX)
Number of subjects: 594
Study: 17533209

Group type: EXPERIMENTAL
Intervention: TLC diet plus soy nuts (25 g of soy protein and 101 mg of aglycone isoflavones)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: TLC diet plus soy nuts
Number of subjects: 60

Group type: COMPARATOR
Intervention: TLC diet alone
Number of subjects: 60
Study: 15232517

Group type: EXPERIMENTAL
Intervention: IT 2.5 mg levobupivacaine + 25 microg fentanyl (LF)
Number of subjects: 40

Group type: COMPARATOR
Intervention: IT 2.5 mg levobupivacaine (L)
Number of subjects: 40
Study: 11146073

Group type: EXPERIMENTAL
Intervention: 25 microg misoprostol
Number of subjects: 185

Group type: EXPERIMENTAL
Intervention: 50 microg misoprostol
Number of subjects: 185
Study: 10079864

Group type: EXPERIMENTAL
Intervention: Antibiotic therapy (specific antibiotics not detailed)
Number of subjects: 387

Group type: EXPERIMENTAL
Intervention: Immunotherapy (immunocorrection)
Number of subjects: 387

Group type: EXPERIMENTAL
Intervention: Various physiochemical methods in complex treatment
Number of subjects: 387
Study: 7974832

Group type: EXPERIMENTAL
Intervention: Vitamin provision in newborns from healthy mothers
Number of subjects: 0

Group type: COMPARATOR
Intervention: Vitamin provision in newborns from mothers with hypertensive disease
Number of subjects: 0
Study: 2610720

Group type: EXPERIMENTAL
Intervention: Sustained Release Capsule (Elantan), 50 mg
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Sustained Release Tablet, 50 mg
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Sustained Release Capsule, 100 mg
Number of subjects: 18

Group type: COMPARATOR
Intervention: Non Sustained Release Tablets, 40 mg
Number of subjects: 18

Group type: COMPARATOR
Intervention: Non Sustained Release Tablets, 2 x 20 mg
Number of subjects: 18
Study: 56903

Group type: EXPERIMENTAL
Intervention: Hydroxyethylstarch
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Dextran 60
Number of subjects: 0

Group type: COMPARATOR
Intervention: Electrolyte group
Number of subjects: 0
Study: 31445343

Group type: EXPERIMENTAL
Intervention: Lithium
Number of subjects: 482

Group type: EXPERIMENTAL
Intervention: Quetiapine plus adjunctive personalized therapy
Number of subjects: 482
Study: 29088099

Group type: EXPERIMENTAL
Intervention: Anserine/carnosine supplementation (ACS) 1.0 g (3:1) for 3 months
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Anserine/carnosine supplementation (ACS)
Number of subjects: 60
Study: 25744209

Group type: EXPERIMENTAL
Intervention: 3-session prevention program
Number of subjects: 236
Study: 23890906

Group type: EXPERIMENTAL
Intervention: Large patent foramen ovale (PFO)
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Moderate or large PFO
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Atrial septal aneurysms
Number of subjects: 80

Group type: COMPARATOR
Intervention: PFO size and headache days
Number of subjects: 80
Study: 22185740

Group type: EXPERIMENTAL
Intervention: Levocetirizine (5 mg)
Number of subjects: 31

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 31
Study: 18585750

Group type: EXPERIMENTAL
Intervention: Two-interval forced choice (2-IFC) procedure
Number of subjects: 0

Group type: COMPARATOR
Intervention: Two successive Yes-No signal detection tasks
Number of subjects: 0